	US 11,897,869 B2
	JAK1 selective inhibitors
Karl Magnus Nilsson, Mölndal (SE); Annika Birgitta Margareta Åstrand, Mölndal (SE); Anna Ingrid Kristina Berggren, Mölndal (SE); Johan R. Johansson, Mölndal (SE); Matti Juhani Lepistö, Mölndal (SE); Sameer Pralhad Kawatkar, Wilmington, DE (US); Qibin Su, Wilmington, DE (US); and Jason Grant Kettle, Cambridge (GB)
Assigned to AstaZeneca AB, Sodertalje (SE)
Filed by AstraZeneca AB, Södertälje (SE)
Filed on Mar. 1, 2021, as Appl. No. 17/188,097.
Application 17/188,097 is a continuation of application No. 16/478,168, granted, now 10,961,228, previously published as PCT/EP2018/051038, filed on Jan. 16, 2018.
Claims priority of provisional application 62/447,057, filed on Jan. 17, 2017.
Prior Publication US 2021/0188821 A1, Jun. 24, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 403/14 (2006.01); A61P 17/14 (2006.01); A61K 9/00 (2006.01)

CPC C07D 403/14 (2013.01) [A61K 9/0075 (2013.01); A61P 17/14 (2018.01)]

24 Claims

1. A method of treating a JAK1-related disorder in a subject comprising administering a therapeutically effective amount of the compound (R)-N-(3-(5-fluoro-2-(2-fluoro-3-(methylsulfonyl)phenylamino)pyrimidin-4-yl)-1H-indol-7-yl)-3-methoxy-2-(4-methylpiperazin-1-yl)propanamide, or a pharmaceutically acceptable salt thereof.